Veloxis Pharmaceuticals has agreed to pay more than $46 million to resolve criminal and civil allegations that it used kickbacks to drive prescriptions and purchases of Envarsus XR, its kidney-transplant drug. According to the Department of Justice, the resolution includes a deferred prosecution agreement tied to a criminal information filed in the U.S. District Court for the District of Massachusetts, underscoring the government’s continued focus on pharmaceutical marketing practices that allegedly influence prescribing decisions.
The matter is significant because it combines both criminal and civil exposure in a single healthcare-fraud resolution. On the criminal side, a deferred prosecution agreement allows the company to avoid prosecution if it complies with specified conditions, typically including ongoing cooperation, compliance enhancements, and reporting obligations. On the civil side, the settlement reflects the substantial financial risk companies face when alleged kickbacks implicate federal healthcare programs and trigger False Claims Act-related theories of liability.
At the center of the case is the Anti-Kickback Statute, a law that prohibits offering or paying remuneration to induce referrals or purchases reimbursable by federal healthcare programs. For drug manufacturers, AKS scrutiny often extends beyond obvious cash payments and into speaker programs, advisory arrangements, copay assistance structures, and other financial relationships with providers, pharmacies, or patients. DOJ’s action against Veloxis is another reminder that the government views improper influence over prescribing and purchasing decisions as a priority enforcement area, especially in markets involving high-cost specialty drugs and vulnerable patient populations such as transplant recipients.
For litigators, the case is a useful example of how parallel criminal and civil investigations can shape settlement leverage and timing. A deferred prosecution agreement can resolve immediate criminal risk while still leaving the company to negotiate the broader civil fallout. Defense counsel will also note the importance of early internal investigations, document preservation, and careful management of communications with regulators once a kickback inquiry begins.
For in-house counsel and compliance teams, the takeaway is more practical: sales and patient-support programs need to be tested not just for business effectiveness, but for AKS risk. Compensation structures, field reimbursement support, grants, speaker events, and interactions with pharmacies and prescribers should all be reviewed with an eye toward whether they could be characterized as inducements. In the current enforcement climate, the cost of getting that analysis wrong can include criminal filings, corporate integrity obligations, and eight-figure settlements.
The District of Massachusetts has remained an important venue for healthcare-fraud enforcement, and this resolution reinforces how aggressively DOJ is policing pharmaceutical commercialization strategies. Legal departments tracking enforcement trends should view the Veloxis matter as a clear signal that kickback allegations remain one of the fastest paths from compliance concern to enterprise-level legal risk.